• Reference Citation Analysis
  • v
  • v
  • Find an Article
  • Find an Author
Download
Number Citation Analysis
1
Kiguli-Malwadde E, Forster M, Eliaz A, Celentano J, Chilembe E, Couper ID, Dassah ET, De Villiers MR, Gachuno O, Haruzivishe C, Khanyola J, Martin S, Motlhatlhedi K, Mubuuke R, Mteta KA, Moabi P, Rodrigues A, Sears D, Semitala F, von Zinkernagel D, Reid MJA, Suleman F. Comparing in-person, blended and virtual training interventions; a real-world evaluation of HIV capacity building programs in 16 countries in sub-Saharan Africa. PLOS Glob Public Health 2023;3:e0001654. [PMID: 37486898 PMCID: PMC10365303 DOI: 10.1371/journal.pgph.0001654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Accepted: 06/05/2023] [Indexed: 07/26/2023]
2
Waterhouse D, Rothschild S, Dooms C, Mennecier B, Bozorgmehr F, Majem M, van den Heuvel M, Linardou H, Chul-Cho B, Roberts-Thomson R, Okamoto I, Blais N, Schvartsman G, Holmskov K, Chmielewska I, Forster M, Stollenwerk B, Obiozor C, Wang Y, Novello S. 40 Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00258-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
3
Sacher A, Patel M, Miller W, Desai J, Garralda E, Bowyer S, Kim T, De Miguel M, Falcon A, Krebs M, Lee J, Cheng M, Han SW, Shacham-Shmueli E, Forster M, Jerusalem G, Massarelli E, Paz-Ares Rodriguez L, Prenen H, Walpole I, Arbour K, Choi Y, Dharia N, Lin M, Mandlekar S, Royer Joo S, Shi Z, Schutzman J, LoRusso P. OA03.04 Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
4
Forster M, Krebs M, Majem M, Peguero J, Clay T, Felip E, Iams W, Roxburgh P, Doger B, Bajaj P, Kefas J, Scott J.A, Barba Joaquín A, Mueller C, Triebel F. EP08.01-109 TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
5
Ibrahim NK, Schreek S, Cinar B, Loxha L, Bourquin JP, Bornhauser B, Forster M, Stanulla M, Gutierrez A, Hinze L. SOD2 Promotes Acute Leukemia Adaptation to Amino Acid Starvation Through the N-Degron Pathway. KLINISCHE PADIATRIE 2022. [DOI: 10.1055/s-0042-1748744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
6
Graham R, Kolluri K, Davies A, Weil B, Day A, Popova B, Ngai Y, Fullen D, Teixeira V, Forster M, Lowdell M, Janes S. Mesenchymal Stem/Stromal Cells: ANALYSIS OF PATIENT PERIPHERAL BLOOD SAMPLES TO ASSESS IMMUNOGENICITY OF MSCTRAIL, A NOVEL ANTI-CANCER THERAPY. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00168-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
7
Krebs M, Majem Tarruella M, Forster M, Peguero J, Clay T, Felip E, Iams W, Roxburgh P, Doger de Spéville B, Bajaj P, Mueller C, Triebel F. 11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]  Open
8
Samuel E, Rologi E, Fraser H, Sassi M, Pruchniak M, Kotsiou E, Robinson J, Benzekhroufa K, Goodsell L, Carolan C, Saggese M, Grant M, Samways B, Kotecha P, Schmitt A, Lawrence D, Forster M, Turajlic S, Lowdell M, Quezada S. 58P Validation of the Achilles VELOS process 2 manufacturing platform for the treatment of solid cancer: GMP scale runs generate a significant dose boost of highly potent clonal neoantigen reactive T-cells. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]  Open
9
Lee A, Girling B, Patel G, Sawhney P, Luong M, Ohana D, Forster M, Lee S. MA13.06 Improved Outcomes for Patients Developing Any Immune-Related Adverse Events in Advanced NSCLC Treated With Pembrolizumab Monotherapy. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
10
Zeiner PS, Filipski K, Forster M, Voss M, Fokas E, Herrlinger U, Harter PN, Steinbach JP, Ronellenfitsch MW. P14.11 Severe treatment-induced myelosuppression is more frequent in female malignant glioma patients and associated with reduced overall survival. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab180.136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
11
Watson M, Chambers P, Shiu KK, Bridgewater J, Desai M, Roylance R, Tailor A, Masento S, Forster M, Al Moubayed N. 1859P Using deep learning with demographic and laboratory values from baseline to cycle 2 to predict subsequent renal and hepatic function. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]  Open
12
Forster M, Mendes R, Guerrero Urbano T, Evans M, Lei M, Spanswick V, Miles E, Simões R, Wheeler G, Forsyth S, White L. 866P ORCA-2: A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced (LA) squamous cell carcinoma of the head and neck (HNSCC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]  Open
13
Syeed Z, Forster M, Boukovinas I, Nutting C, Carnell D, Guerrero Urbano T, Sibtain A, Kalavrezos N, Patel G, Al Bakir M, Arkenau HT, Levva S, Gonnet P, Morelli C, Guerriero S, Rofei M, Formica V, Patrikidou A. 889P Development of a head and neck immune prognostic index (HN-IPI) classification for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who received immune checkpoint inhibitors (ICIs). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]  Open
14
Patel G, Sawhney P, Ohana D, Luong M, Wong Y, Lee A, Forster M. 31P Safety and efficacy of immune checkpoint inhibitors in cancer patients with pre-existing autoimmune disease: A UK tertiary cancer centre experience. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.01.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]  Open
15
Forster M, Felip E, Doger B, Lopez Pousa A, Carcereny E, Bajaj P, Church M, Peguero J, Roxburgh P, Triebel F. 927P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1042] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]  Open
16
Forsyth S, Yip K, Foran B, Gougis P, Wheeler G, White L, Chandrakumar A, Blair K, Pathak Y, Spanswick V, Lowe H, Hartley J, Forster M. 979TiP POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status 2 with recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]  Open
17
Davies A, Sage E, Kolluri K, Graham R, Weil B, Rego R, Bain O, Patrick P, Champion K, Day A, Popova B, Wheeler G, Fullen D, Kalbur T, Forster M, Lowdell M, Janes S. P2.01-16 TACTICAL: A Phase I/II Trial to Assess the Safety and Efficacy of MSCTRAIL in Metastatic Lung Adenocarcinoma. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
18
Gomes F, Yip K, Tokaca N, Greystoke A, Escriu C, Conibear J, Ghosh S, Doherty G, Funingana I, Ahmad T, Ahmed S, Cox R, Newsom-Davis T, Mills H, Shah R, Dorey N, Harle A, Dancey G, Baijal S, Geldart T, Ghafoor Q, Tarver K, Talbot T, Forster M, Cove-Smith L, Califano R, Blackhall F, Popat S, Summers Y. The ALK project: a real-world national network and database. Lung Cancer 2019. [DOI: 10.1016/s0169-5002(19)30121-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
19
Herbst R, Garon E, Kim DW, Chul Cho B, Pérez Gracia J, Han JY, Dubos Arvis C, Majem M, Forster M, Monnet I, Novello S, Szalai Z, Gubens M, Su WC, Ceresoli G, Samkari A, Jensen E, Lubiniecki G, Baas P. Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy511.003] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
20
Herbst R, Garon E, Kim DW, Chul Cho B, Pérez Gracia J, Han JY, Dubos Arvis C, Majem M, Forster M, Monnet I, Novello S, Szalai Z, Gubens M, Su WC, Ceresoli G, Samkari A, Jensen E, Lubiniecki G, Baas P. Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.075] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
21
Forster M, Moreno V, Calvo E, Olmedo M, Lopez-Criado M, Lopez-Vilariño J, Nuñez R, Kahatt C, Soto-Matos A. P1.12-20 Overall Survival with Lurbinectedin Plus Doxorubicin in Relapsed SCLC. Results from an Expansion Cohort of a Phase Ib Trial. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.855] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
22
Fennell D, Danson S, Forster M, Talbot D, Woll P, Child J, Ngai Y, Farrelly L, Hackshaw A, Sharkey A, Busacca S, Hastings R, Barnes D, Nicolson M, Taylor P, Ahmed S, Wheeler G. MA12.05 Phase 1 Study of HSP90 Inhibitor Ganetespib with Pemetrexed and Cisplatin/Carboplatin Chemotherapy for Pleural Mesothelioma. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
23
Forster M, Baumgarten P, Gessler F, Maurer G, Senft C, Hattingen E, Seifert V, Harter P, Franz K. P01.063 Influence of Pregnancy on Glioma Patients. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
24
Kilinc F, Noack A, Lortz I, Seifert V, Behrens M, Forster M. P01.164 Cognitive and neuropsychological outcome after awake surgery for left frontal and left temporal tumor resection. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
25
Thakur N, Senft C, Seifert V, Forster M. P01.107 Resection of supratentorial lesions employing a combined surgical aspiration and monopolar stimulationdevice. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
26
Steidl E, Zeiner P, Wagner M, Fokas E, Forster M, Ronellenfitsch M, Steinbach JP, Harter PN, Bähr O. P01.101 Treatment and survival of patients with lower grade glioma according to the 2007 and the 2016 WHO classification: A retrospective analysis of 423 patients. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
27
Kieffer R, Bartnik L, Bergamaschi M, Bleko VV, Billing M, Bobb L, Conway J, Forster M, Karataev P, Konkov AS, Jones RO, Lefevre T, Markova JS, Mazzoni S, Padilla Fuentes Y, Potylitsyn AP, Shanks J, Wang S. Direct Observation of Incoherent Cherenkov Diffraction Radiation in the Visible Range. Phys Rev Lett 2018;121:054802. [PMID: 30118307 DOI: 10.1103/physrevlett.121.054802] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Indexed: 06/08/2023]
28
Lindsay CR, Jamal-Hanjani M, Forster M, Blackhall F. KRAS: Reasons for optimism in lung cancer. Eur J Cancer 2018;99:20-27. [PMID: 29894909 DOI: 10.1016/j.ejca.2018.05.001] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Revised: 03/21/2018] [Accepted: 05/13/2018] [Indexed: 01/07/2023]
29
Sinharay R, Mithra S, Patel P, Ah-Moye A, Morrow S, Khiroya R, Falzon M, Borg E, Ahmed T, Forster M, Navani N. EGFR mutation specific immunohistochemistry revolutionises time to treatment with tyrosine kinase inhibitors (TKIs). Lung Cancer 2018. [DOI: 10.1016/s0169-5002(18)30085-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
30
Forster M, Olmedo M, Calvo E, Moreno V, Lopez Criado M, Lopez-Vilariño J, Kahatt C, Lardelli P, Nuñez R, Soto-Matos A. Activity of lurbinectedin as single agent and in combination in patients with advanced small cell lung cancer (SCLC). Lung Cancer 2018. [DOI: 10.1016/s0169-5002(18)30192-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
31
Calvo E, Forster M, Moreno V, Olmedo M, Criado ML, Lopez-Vilariño J, Kahatt C, Soto-Matos A. MA 01.05 Activity and Safety of the Combination of PM01183 and Doxorubicin in Relapsed SCLC. Final Results of a Phase Ib Trial. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
32
Calvo E, Moreno V, Flynn M, Holgado E, Olmedo ME, Lopez Criado MP, Kahatt C, Lopez-Vilariño JA, Siguero M, Fernandez-Teruel C, Cullell-Young M, Soto Matos-Pita A, Forster M. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study. Ann Oncol 2017;28:2559-2566. [PMID: 28961837 PMCID: PMC5834091 DOI: 10.1093/annonc/mdx357] [Citation(s) in RCA: 57] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]  Open
33
Vergote I, Dean E, Lassen U, de Bono J, Drew Y, Machiels JP, Nielsen D, Arkenau HT, Forster M, Jones R, Slomovitz B, Spicer J, Johnson M, Cornez N, Gennigens C, Fulton B, Lisby S, Basse L, Coleman R, Hong D. A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx372.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
34
Uccello M, Kushnir M, Mak G, Murias Henriquez C, Abbosh C, Papadatos-Pastos D, Newsom-Davis T, Ahmad T, Swanton C, Forster M, Lanman R, Faull I, Arkenau HT. Circulating tumour DNA (ctDNA) in the clinical management of patients (pts) with advanced non-small cell lung cancer (NSCLC): A single centre experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx363.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
35
Olmedo Garcia M, Forster M, Calvo E, Moreno V, Lopez Criado M, Lopez-Vilarino de Ramos J, Kahatt C, Lardelli P, Luepke-Estefan X, Soto-Matos A. Activity of lurbinectedin as single agent and in combination in patients with advanced small cell lung cancer (SCLC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx386.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
36
Forster M, Sessa C, Von Moos R, Brown N, Metaxas Y, Griguolo G, Lardelli P, Iglesias J, Fernandez-Teruel C, Jandali U, Soto-Matos S, Stathis A. Phase I study of lurbinectedin (PM01183) in combination with cisplatin (CDDP) with or without aprepitant in patients (pts) with advanced solid tumors. Eur J Cancer 2017. [DOI: 10.1016/s0959-8049(17)30519-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
37
Yip K, Conibear J, Woolf D, Tarver K, Willis B, Hall S, Sun F, Kuhan H, Lambourne B, Piskilidis P, Kussaibati R, Martin L, Satar NA, Gray C, Khan A, Doherty G, Prewett S, Smith M, Dancey G, Patterson D, Rimmer Y, Hollingdale A, Ingle C, Tasigiannopoulos Z, Aslam S, Waite K, Polychronis A, Ghafoor Q, Baijal S, Newsom-Davis T, Shah R, Forster M, Mulatero C, Greystoke A, Postmus P, Blackhall F, Gilligan D. 62: A retrospective multicentre audit of outcome among patients with anaplastic lymphoma kinase (ALK) gene rearrangement positive non-small cell lung cancer (NSCLC) who have been treated with crizotinib in England. Lung Cancer 2017. [DOI: 10.1016/s0169-5002(17)30112-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
38
Darling GR, Forster M, Lin C, Liu N, Raval R, Hodgson A. Chiral segregation driven by a dynamical response of the adsorption footprint to the local adsorption environment: bitartrate on Cu(110). Phys Chem Chem Phys 2017;19:7617-7623. [DOI: 10.1039/c7cp00622e] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
39
Kordbacheh T, Chan C, Bossons A, Franks K, McDonald F, Forster M, Mendes R, Quezada S, Dovedi S, Ralph C, Popat S, Harrington K, Melcher A, Popple A, Illidge T, Faivre-Finn C. 164: PARIS: A phase I study of pembrolizumab anti-PD-1 monoclonal antibody in combination with radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 2017. [DOI: 10.1016/s0169-5002(17)30214-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
40
Kordbacheh T, Chan C, Faivre-Finn C, Franks K, McDonald F, Forster M, Mendes R, Quezada S, Dovedi S, Ralph C, Popat S, Harrington K, Melcher A, Popple A, Illidge T. 168: PD-RAD: A translational study investigating PD-L1 expression after radiotherapy for non-small cell lung cancer (NSCLC). Lung Cancer 2017. [DOI: 10.1016/s0169-5002(17)30218-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
41
Mavrič T, Valant M, Forster M, Cowan A, Lavrenčič U, Emin S. Design of a highly photocatalytically active ZnO/CuWO 4 nanocomposite. J Colloid Interface Sci 2016;483:93-101. [DOI: 10.1016/j.jcis.2016.08.019] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2016] [Revised: 08/08/2016] [Accepted: 08/10/2016] [Indexed: 02/07/2023]
42
Schaefer E, Braiteh F, Forster M, Talbot D, Chandler J, Richards D, Andre V, Estrem S, Pitou C, Tiu R, Brail L, Nikolinakos P. Phase 1b/2 trial of taladegib (LY2940680), a Hh/Smo inhibitor, in combination with carboplatin and etoposide followed by taladegib maintenance in extensive-stage small-cell lung cancer. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32990-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
43
Brown N, Ganguli S, Kirkwood A, Imseeh G, Kristeleit R, Forster M, Meyer T. Clinical outcomes and predicting early death in early phase trials: The NIHR UCLH clinical research facility (CRF) experience. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
44
Kristeleit R, Miller R, Sellers L, Brown N, Gougis P, Boyd A, Morris G, Payne H, Hughes S, Forster M, Linch M. A first-in-human (FIH) phase I/II, dose escalation, pharmacokinetic (PK) study to assess the safety and tolerability of VAL-201 in patients with advanced prostate cancer (APC) and other advanced solid tumours. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
45
Miller R, Brown N, Speirs A, Shaw H, Adeleke S, Gougis P, Bennett P, Meyer T, Swanton C, Forster M, Kristeleit R. The use of next generation sequencing (NGS) to guide patient selection for phase 1 clinical trials. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]  Open
46
Batchelor D, Aygül U, Dettinger U, Ivanovic M, Tournebize A, Mangold S, Forster M, Scherf U, Peisert H, Chassé T. Insight into the orientation of LBG polymer films by XANES experiment and calculation. Eur Polym J 2016. [DOI: 10.1016/j.eurpolymj.2016.04.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
47
Knaapila M, Stepanyan R, Torkkeli M, Haase D, Fröhlich N, Helfer A, Forster M, Scherf U. Effect of side-chain asymmetry on the intermolecular structure and order-disorder transition in alkyl-substituted polyfluorenes. Phys Rev E 2016;93:042504. [PMID: 27176345 DOI: 10.1103/physreve.93.042504] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Indexed: 11/07/2022]
48
Ruparel M, Ejaz A, Chauhan N, Ridge M, Chung D, Succony L, Banka R, Thakrar R, Kumar N, Sage E, Forster M, Janes S, Newsom-Davis T, Ahmad T, Navani N. 23 Characteristics of lung cancer patients diagnosed following emergency admission. Lung Cancer 2016. [DOI: 10.1016/s0169-5002(16)30040-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
49
Forster M, Raval R. Simple rules and the emergence of complexity in surface chirality. Chem Commun (Camb) 2016;52:14075-14084. [DOI: 10.1039/c6cc06523f] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
50
Eychmüller S, Forster M, Gudat H, Lütolf UM, Borasio GD. Undergraduate palliative care teaching in Swiss medical faculties: a nationwide survey and improved learning objectives. BMC Med Educ 2015;15:213. [PMID: 26614121 PMCID: PMC4662810 DOI: 10.1186/s12909-015-0485-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2014] [Accepted: 11/09/2015] [Indexed: 05/26/2023]
PrevPage 1 of 3 123Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA